Sign In
13 Dec 2021 12:46
13 December 2021
Diurnal Group plc
("Diurnal" or the "Company")
Block Admission Application
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that an application has been made to the London Stock Exchange for a block admission of 5,775,000 ordinary shares of 5 pence each ("Ordinary Shares") to be admitted to trading on AIM ("Block Admission").
The Block Admission relates to Ordinary Shares that will be issued from time to time in accordance with the exercise of options under the Company's Long Term Incentive Plan ("LTIP") and historic unapproved share option schemes. All Ordinary Shares issued pursuant to the Block Admission above will rank pari passu with the existing Ordinary Shares.
It is expected that the Block Admission will become effective on or around 17 December 2021.
In addition, 90,050 new Ordinary Shares have been issued in respect of satisfaction of the exercise of options under the LTIP and admission to trading of these shares will be pursuant to the Block Admission ("New Shares").
Total voting rights
Following the issue of the New Shares, the total number of voting rights of the Company is 169,143,851 shares. This figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in Diurnal under the FCA's Disclosure and Transparency Rules.
The Company intends to notify on a monthly basis when there are changes to the issued share capital of the Company, and these monthly figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company, under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, Chief Executive Officer | |
Richard Bungay, Chief Financial Officer | |
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker) | +44 (0)20 7886 2500 |
Corporate Finance: Freddy Crossley, Emma Earl | |
Corporate Broking: Rupert Dearden | |
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | +44 (0) 20 7710 7600 |
Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea | |
Corporate Broking: Nick Adams | |
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
Alex Davis | |
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk.
Follow the stocks
